Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: allatwwk who wrote (31318)	7/8/2015 2:53:52 PM
From: gaduntz73	Respond to of 63324

It really shouldn.t be that shocking....the SLE indication and trial process has been a burial ground for dozens of drugs.....wall street bet big on the the only one to get approved, Benlysta, and lost big money anyway...so the confidence necessary for a big valuation based on expectations is nil. Add to that the consistent delays in other product development and licensing deals, and the resultant necessary repetitive dilutions, including the latest huge overhang (relative to mkt cap) of cvts which has led to significant short hedging and you have our current predicament. Since I've always been a believer in emab, and have given ucb the longest of leashes to get the job done, what keeps me here is the potentail for revaluation if the data is really, really good...altho its likely to be a show-me story for the street.